神经炎症
医学
疾病
神经学
免疫学
多发性硬化
干扰素
神经科学
发病机制
免疫系统
细胞因子
小胶质细胞
神经免疫学
α-干扰素
生物信息学
炎症
自身免疫性疾病
自身免疫
中枢神经系统
自身抗体
梅德林
作者
Daniel C. Shippy,Michael L. Sande,Tyler K. Ulland
标识
DOI:10.1186/s12974-026-03828-w
摘要
Type-1 interferons (IFN-1) are a pleiotropic group of cytokines initially known for their antiviral activity, but recent studies highlight a vital role of IFN-1 in central nervous system (CNS) homeostasis, brain aging, and neurodegeneration. Alzheimer’s disease (AD) is an age-related neurodegenerative disorder with a complex etiology. The hallmark signs of AD that appear in the brain are amyloid-β (Aβ) plaques and intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau. Neuroinflammation facilitated primarily by microglia is known to drive amyloid and tau pathology, with evidence suggesting IFN-1 as a key player in AD pathogenesis. Activated microglia secrete IFN-1 in response to Aβ accumulation which activates the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) (JAK/STAT) pathway as well as the cyclic GMP–AMP synthase (cGAS)/stimulator of interferon genes (STING) (cGAS/STING) pathway, resulting in the expression of interferon-stimulated genes (ISGs). Implications of IFN-1 signaling during AD development include neuroinflammation, alterations in microglial morphology (microglial dysfunction), synapse/neuron loss, and cognitive impairment. Additionally, studies suggest blocking/attenuating the IFN-1 response results in reduced AD pathology and improved behavioral deficits. Here, we review the role of IFN-1 in AD pathogenesis. The ability to attenuate IFN-1, coupled with the well-established role of IFN-1 in AD pathogenesis, supports the notion that targeting this neuroinflammatory pathway may be a potential therapeutic strategy for AD.
科研通智能强力驱动
Strongly Powered by AbleSci AI